Si-bone, Inc. · NASDAQ:SIBN
Si-bone — Investor Presentation (January 2023)
25 slides from Si-bone's investor presentation, Jan 9, 2023
Slide 1: Corporate Overview January 2023
1 Corporate Overview January 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements,” which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as “intends,” “estimates,
Slide 3: Transforming & Leading the Sacropelvic Space
Market Leadership Differentiated Platform Clinical and Educational Focus Expanding Addressable Markets $2.4B U.S. annual SIJF opportunity 5-year SIJF clinical data SI-BONE SImulator™ advanced training platform Trauma pelvic ring fracture solution 279K U.S. annual SIJF procedures opportunity Universa
Slide 4: Setup to Deliver Strong and Sustainable Long-term Growth
▪ SI SImulator introduced ▪ Product / solutions launched ▪ Clinical trial results 4 Setup to Deliver Strong and Sustainable Long-term Growth ▪ iFuse 3D launch ▪ IPO ▪ Bedrock launch ▪ LOIS clinical Trial (5-yr data) ▪ SIFI Clinical Trial ▪ INSITE Clinical Trial ▪ iFuse launch ▪ iFuse-TORQ launch ▪ i
Slide 5: Entering 2023 With Accelerating Momentum in the U.S.
Entering 2023 With Accelerating Momentum in the U.S. Note: As of January 9, 2023 Note: The fourth quarter and full year 2022 revenue and cash and marketable securities included in this release are preliminary and prior to the completion of SI-BONE's f inancial closing procedures and audit procedures
Slide 6: Growth Driven by Robust Surgeon Engagement + Procedure Demand
Growth Driven by Robust Surgeon Engagement + Procedure Demand Note: As of January 9, 2023 Note: The fourth quarter and full year 2022 revenue and cash and marketable securities included in this release are preliminary and prior to the completion of SI-BONE's f inancial closing procedures and audit p
Slide 7: Operating Leverage Driving Lower Cash Usage
Operating Leverage Driving Lower Cash Usage Note: As of January 9, 2023 Note: The fourth quarter and full year 2022 revenue and cash and marketable securities included in this release are preliminary and prior to the completion of SI-BONE's f inancial closing procedures and audit procedures by its e
Slide 8: Pioneering sacropelvic surgical solutions
Pioneering sacropelvic surgical solutions 8 >75,000 Procedures >3,000 Surgeons >300M U.S. Covered Lives Note: As of January 9, 2023
Slide 9: Major Joints Market
LAST JOINT LARGEST JOINT SI JO INT Major Joints Market 9
Slide 10: 30M+ in the U.S. Suffer From Lower Back Pain
10 30M+ in the U.S. Suffer From Lower Back Pain 4.7M SI joint pain sufferers 1.4M Eligible for surgery Each sy mbol represents 150K people Sources: Jensen M, Brant-Zawadzki M, Obuchowski N, et al. Magnetic Resonance Imaging of the Lumbar Spine in People Without Back Pain. N Engl J Med. 1994;331:69-1
Slide 11: A Major Gap in Sacroiliac Joint Therapy
A Major Gap in Sacroiliac Joint Therapy NON-SURGICAL MANAGEMENT SURGERY MEDICATIONS, PHYSICAL THERAPY THERAPEUTIC INJECTIONS RADIO-FREQUENCY ABLATION OPEN SI JOINT FUSION MIS SI JOINT FUSION 11
Slide 12: Diagnostic Algorithm Acceptance and Adoption
Diagnostic Algorithm Acceptance and Adoption Source: Petersen, et al. BMC Musculoskeletal Disorders. 2017;18(1):188. DOI 10.1186/s 12891-017-1549-6 PATIENT HISTORY PROVOCATIVE TESTS LOCAL ANESTHETIC INJECTION MEDICARE (MACs) PRIVATE PAYORS Accuracy equals or exceeds other lumbar spine diagnoses 12
Slide 13: Comprehensive Sacropelvic Surgical Solutions
Comprehensive Sacropelvic Surgical Solutions 13 Platform Technologies Enabling Technologies iFuse and iFuse-3D™ iFuse-TORQ™ iFuse Navigation iFuse Decorticator iFuse Neuromonitoring iFuse Robotics iFuse Bone® iFuse Bedrock Granite™
Slide 14: Clinically Proven Minimally Invasive Solution
Clinically Proven Minimally Invasive Solution >33,000 PROCEDURES REPRESENTATIVE COMPETITOR CANCELLOUS BONE 3D-PRINTED iFUSE-3D TPS-COATED iFUSE 3 MONTH SHEEP STUDY* ▪ Proven triangular design and procedure ▪ Porous, 3D-printed titanium implant ▪ Bony on-growth, in-growth, through-growth* * MacBarb R
Slide 15: Proprietary, Differentiated Technology
15 Proprietary, Differentiated Technology iFuse SI Screws Rotation 6x resistance (vs. 12mm Rialto screw)1 ▪ 1x resistance Strength 3x strength (vs. stand 8.0mm cannulated screw)2 ▪ 1x strength Safety Low complication rate3 ▪ No known aggregate published data Revision 3.5% (4-year)4 ▪ 6.1% @
Slide 16: Intellectual Property Overview
Intellectual Property Overview ▪ 64 issued patents: U.S. (49), OUS (15) ▪ 51 pending patents: U.S. (32), OUS (19) ▪ iFuse patents cover until November 2024 ▪ iFuse-3D™ patents cover until September 2035 SHAPE Joint … fused … a rectilinear bone fusion implant… across the joint APPROACH Lateral insert
Slide 17: Robust Clinical Evidence
Robust Clinical Evidence • 100+ peer-reviewed published papers • 5-year long-term, prospective data • Two Level 1 randomized studies 17 www.si-bone.com/results
Slide 18: Patient Experience
Patient Experience 95%Patient satisfaction1 Clinically meaningful threshold at 15 pts 1. Whang PG, et al. Long-Term Prospective Clinical And Radiographic Outcomes After Minimally Invasive Lateral Transiliac Sacroiliac Joint Fusion Using Triangular Titanium Implants. Med Devices (Auckl). 2019;12:411-
Slide 19: SALLY Prospective Clinical Trial: iFuse-3D 2-year Outcomes
19 SALLY Prospective Clinical Trial: iFuse-3D 2-year Outcomes1 Rapid, marked and durable improvements in pain, patient function and quality of life VAS Pain Reduction ODI Disability Improvement Decreased Opioid Use 57-point improvement (MCID 20 points) 25-point improvement (MCID 15 points) 59% at ba
Slide 20: iFuse-TORQ: Cutting Edge Pelvic Fixation and Fusion
iFuse-TORQ: Cutting Edge Pelvic Fixation and Fusion Large, Adjacent Market 1 FuSIon 3D™ Surface for Osseointegration Differentiated Technology TORQLock™ Threads2 10x rotational resistance on insertion vs. trauma screws Competitive Advantages ~$350 million Pelvic Trauma opportunity 20 1. Based on int
Slide 21: iFuse Bedrock Granite: Optimized for Fusion and Fixation
21 Large, Adjacent Market ~$250 million Adult Spinal Deformity opportunity1 Competitive Advantages Breakthrough Device Designation by the FDA Expanded Rod Combability allows use with wide variety of pedicle screw systems Up to $9,828 New Technology Add-On Payment (NTAP) 1. Based on internal estimate
Slide 22: SI-BONE SImulator Surgeon Training System
SI-BONE SImulator Surgeon Training System 22 ▪ 25 SImulators deployed in the U.S. and Internationally ▪ Driving surgeon engagement and active surgeon growth ✓ On-demand, anytime, anywhere ✓ No surgeon travel ✓ Radiation-free virtual CTs ✓ Eliminate cadaver costs ✓ All three procedures and morphologi
Slide 23: Differentiated Portfolio Complimented By Strong Fundamentals
Differentiated Portfolio Complimented By Strong Fundamentals ~$96M i n cash and equ ivalen ts as of December 31 , 2022 ATTRACTIVE FINANCIAL PROFILE ROBUST DATA REIMBURSEMENT ADVANTAGE >300M COVERED LIVES EXPANDING ADDRESSABLE MARKET ~84-85% FY22E GROSS MARGIN NTAP IFUSE BEDROCK GRANITE ~28% 4Q22E US
Slide 24: Disclosure
DisclosureDisclosure The iFuse Implant System® and iFuse Bedrock Granite Implant System are both intended for sacroiliac fusion for the following conditions: • Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions
Slide 25: Pioneering sacropelvic surgical solutions
Pioneering sacropelvic surgical solutions 25 >75,000 Procedures >3,000 Surgeons >300M U.S. Covered Lives Note: As of January 9, 2023